Evidence map›Paper›PMID 40133542›Full record

ArticleCommunications medicine2025

[

Sarah B Gitto, Austin R Pantel, Kara N Maxwell, Daniel A Pryma, Michael D Farwell, Fang Liu, Quy Cao, Sophia R O'Brien, Amy S Clark, Payal D Shah and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects.European journal of nuclear medicine and molecular imaging · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. [Communications medicine · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sarah B Gitto *Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-6496-4528
Austin R Pantel *Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Kara N MaxwellDepartment of Medicine, Division of Hematology and Oncology Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-8192-4202
Daniel A PrymaDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Michael D FarwellDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-0650-4747
Fang LiuDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-2922-4414
Quy CaoDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Sophia R O'BrienDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Amy S ClarkDepartment of Medicine, Division of Hematology and Oncology Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Payal D ShahDepartment of Medicine, Division of Hematology and Oncology Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Elizabeth S McDonaldDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Elizabeth.McDonald@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0002-7209-4216

Funding

Developing PARP-1 PET with companion tissue assay as a precision tool to guide PARPi therapyR37CA277541 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Elizabeth McDonald · 2024 to 2026
$1.6M
NCI NIH HHS R37 CA277541
6 · The paper itself

Abstract

backgroundPoly (ADP-ribose) polymerase inhibitors (PARPi) are approved for Breast Cancer gene (BRCA)-mutant HER2- breast cancer, and there is clinical interest in expanding indications to include homologous recombination deficient (HRD) breast cancers. Yet, response in these populations remains variable, suggesting clinical utility in developing a better biomarker to select patients for PARPi and predict response. Here, we evaluate a radiolabeled PARPi, [

methodsA single-arm prospective observational trial was conducted at the University of Pennsylvania. [

resultsHere we show that baseline [

conclusionsThese early results suggest the potential of [

Identifiers

PMID40133542
PMCPMC11937411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.